Best Nanotechnology Stocks To Watch Now – April 15th

OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of companies that research, develop, and manufacture products using nanotechnology—manipulating materials at the molecular or atomic level. These stocks represent firms that apply innovative nanoscale advancements in various fields such as electronics, healthcare, and energy, offering investors exposure to cutting-edge technological growth. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

OSIS traded up $1.25 on Tuesday, hitting $193.95. The company had a trading volume of 84,187 shares, compared to its average volume of 182,637. OSI Systems has a 1 year low of $126.57 and a 1 year high of $220.00. The firm has a market cap of $3.26 billion, a P/E ratio of 24.96, a PEG ratio of 1.81 and a beta of 1.19. The company’s fifty day moving average price is $195.42 and its 200 day moving average price is $174.86. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded up $0.60 during trading on Tuesday, hitting $58.75. The company had a trading volume of 12,348 shares, compared to its average volume of 25,607. NVE has a 1-year low of $51.50 and a 1-year high of $89.98. The company’s 50 day simple moving average is $66.29 and its 200-day simple moving average is $74.06. The stock has a market cap of $284.17 million, a price-to-earnings ratio of 18.95 and a beta of 1.05.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Biodexa Pharmaceuticals stock traded down $0.28 during mid-day trading on Tuesday, reaching $1.37. 161,648 shares of the company’s stock were exchanged, compared to its average volume of 1,654,904. Biodexa Pharmaceuticals has a twelve month low of $1.14 and a twelve month high of $74.00. The stock’s fifty day simple moving average is $2.67.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN traded down $0.08 on Tuesday, hitting $3.00. 11,223 shares of the company were exchanged, compared to its average volume of 53,766. The company has a market cap of $25.79 million, a price-to-earnings ratio of -0.57 and a beta of 0.46. The firm has a 50-day moving average price of $3.96 and a two-hundred day moving average price of $4.63. Clene has a twelve month low of $2.57 and a twelve month high of $9.20.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of VRPX stock traded up $0.02 during trading hours on Tuesday, reaching $0.28. 10,670 shares of the stock were exchanged, compared to its average volume of 199,854. Virpax Pharmaceuticals has a 12-month low of $0.13 and a 12-month high of $101.00. The business’s fifty day moving average is $3.85 and its two-hundred day moving average is $9.06.